免疫抑制缓释用于治疗同种异体复合组织移植的研究进展

组织工程与重建外科杂志 ›› 2023, Vol. 19 ›› Issue (1): 79-.

免疫抑制缓释用于治疗同种异体复合组织移植的研究进展

出版日期:2023-02-01 发布日期:2023-03-08

Controlled release immunosuppression therapy in vascularized composite allotransplantation

Online:2023-02-01 Published:2023-03-08

摘要/Abstract

摘要：

　同种异体复合组织移植（Vascularized composite allotransplantation，VCA）是帮助肢体和颜面部等组织严重毁损的患者重建功能、恢复美观的重要手段之一。VCA 患者术后需要接受终身的免疫抑制治疗，抑制免疫排斥反应。长期免疫抑制剂管理易引发各种机体的毒副反应，影响生活质量，甚至威胁生命安全。免疫抑制局部缓释治疗可以提高移植物局部的药物浓度，减轻全身毒副作用，相对于全身用药具有一定优势。本文对目前基于各种生物材料的局部缓释给药系统在 VCA 中的应用进行综述。

关键词:

　同种异体复合组织移植 , 　免疫抑制治疗 , 　缓释给药系统 , 　生物材料

Abstract:

　Vascularized composite allotransplantation (VCA) is an effective treatment to restore functional and aesthetic

outcomes for patients suffering from devastating composite tissue loss. Life-long immunosuppression administration is usually

mandatory for VCA patients to avoid immune rejection. However, the subsequent adverse effects would impair life quality or even

cause death. Local delivery of controlled-release immunosuppressants is advantageous on maintaining a high level of medication

and decreasing organ toxicities. In this paper, the biomaterial-based controlled-release systems in VCA were reviewed.

Key words:

Vascularized composite allotransplantation, 　Immunosuppressive therapy, 　Controlled-release system, 　

Biomaterial

邓智中, 周显玉, 刘菲, 等. 免疫抑制缓释用于治疗同种异体复合组织移植的研究进展[J]. 组织工程与重建外科杂志, 2023, 19(1): 79-.

DENG Zhizhong, ZHOU Xianyu, LIU Fei, et al.

Controlled release immunosuppression therapy in vascularized composite allotransplantation [J]. Journal of Tissue Engineering and Reconstructive Surgery, 2023, 19(1): 79-.